Resources
About Us
Home Report
Store
Vaccines Market
Vaccines Market Size, Share, Forecast, & Trends Analysis by Indication (Pneumococcal, Influenza, HPV, DTP, MMR, Hepatitis, COVID-19) Administration (IM, SC, Oral) Type (Inactivated, Combination) Valence (Multivalent, Monovalent) - Global Forecast to 2031
Report ID:MRHC - 104377 Pages: 270 May-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursThe Vaccines Market was valued at $59.55 billion in 2023. This market is expected to reach $71.5 billion by 2031, from an estimated $60.98 billion in 2024, at a CAGR of 2.3% during the forecast period 2024-2031.
Vaccines Market Size & Forecast
The market’s growth is majorly driven by the strong pipeline for vaccines, increasing government initiatives toward immunization, and technological advancements in the vaccine industry. Moreover, the rising prevalence of diseases, growing focus on therapeutic vaccines, and growth prospects in emerging markets are expected to offer growth opportunities for the players operating in this market.
Vaccines Market Growth Drivers
Technological Advancements in Vaccine Administration
Vaccine technology has evolved significantly during the last decade, profoundly changing the future of vaccine development. The introduction of genetic engineering has fueled many advances in vaccine development programs, leading to new products. Various virus vaccines that use the attenuated form of the virus have been developed through these methods. Also, new technologies enable the faster detection of viruses and allow for concentration levels to be kept high enough to generate an immune response.
Recent vaccine technologies are largely driven by the need to accelerate response times against emerging threats and make vaccines available for quick deployment. The increasing need to develop vaccines against difficult targets and improve delivery systems for maximum potency is also the focus of innovation in the vaccine industry. The development of synthetic vaccine candidates, genomic analysis of disease progression and vaccine response, structure-based antigen design, and nanoparticle delivery systems are some of the technological advancements in vaccine delivery.
Therefore, technological advancements are expected to drive the emergence of new and more effective vaccines for various new indications, fueling the growth of the vaccine market.
Click here to: Get Free Sample Pages of this Report
Strong Product Pipeline for Vaccines
Over the last decade, the field of vaccine development has received huge support from the pharmaceutical industry as well as governments worldwide due to successful vaccination programs that helped in the eradication of infectious diseases such as chickenpox and polio globally, saving billions of dollars in healthcare expenditure. Vaccines are one of the most powerful and cost-effective health interventions available. Yet, many preventable diseases still cost millions of lives and billions of dollars every year. GlaxoSmithKline plc (U.K.), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), Daiichi Sankyo Co., Ltd. (Japan), and Takeda Pharmaceutical Co., Ltd. (Japan) are some of the major providers of vaccines in the global market. These companies are continuously engaged in developing new vaccines for new indications. The strong product pipelines of these companies indicate the growing demand for vaccines in the global market.
Some companies have portfolios of highly profitable vaccines and small vaccine pipelines. In such cases, the companies’ access considerations mainly depend upon pricing, registration, and supply. Other companies have limited product portfolios but larger pipelines supported by proportionally high investments in vaccine R&D. These companies are focused on ensuring the development of effective and accessible vaccines to meet global health needs.
Vaccines Market Opportunity
Rising Prevalence of Diseases
The world is becoming increasingly interconnected, where cross-border travel allows diseases to spread quicker. Today, many vaccine manufacturers are focused on developing vaccines to prevent diseases of epidemic potential and improving the priority of such vaccines globally, creating market potential.
Also, the prevalence of infectious diseases is on the rise. According to the World Health Organization (WHO), infectious diseases such as tuberculosis (TB) are major causes of death worldwide. In 2022, 10.6 million people suffered from TB, and 1.3 million died from the disease, with over 80% of TB-related deaths recorded in low- and middle-income countries. Therefore, due to the rising prevalence of infectious diseases, there has been an increase in research activities to design vaccines, with a simultaneous increase in the emergence of new vaccines against infectious diseases.
Vaccines Market Analysis: Key Findings
By Indication: In 2024, the Pneumococcal Diseases Segment to Dominate the Vaccines Market
Based on indication, the vaccines market is segmented into pneumococcal diseases, influenza, human papillomavirus (HPV), diphtheria, tetanus, pertussis (DTP), meningococcal disease, measles, mumps, rubella (MMR), rotavirus, poliomyelitis (polio), hepatitis, COVID-19, and other indications. In 2024, the pneumococcal diseases segment is expected to account for the largest share of 13.9% of the vaccines market. The large market share of this segment can be attributed to the rising incidence of pneumococcal diseases such as pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis; the development of quality vaccines such as PPSV23; and initiatives by government and private sector organizations to prevent and control outbreaks of pneumococcal disease.
The pneumococcal disease segment is also projected to register the highest CAGR of 2.7% during the forecast period of 2024-2031. This is due to growing awareness regarding the importance of influenza vaccination and increasing clinical trial support.
By Route of Administration: In 2024, the Intramuscular (IM) Segment to Dominate the Vaccines Market
Based on route of administration, the vaccines market is segmented into intramuscular (IM), subcutaneous (SC), oral, and other route of administration. In 2024, the Intramuscular (IM) segment is expected to account for the largest share of the vaccines market. The large market share of this segment can be attributed to the ease of intramuscular administration and quick absorption of vaccines administered through the intramuscular route.
By Type: In 2024, the Subunit & Conjugate Vaccines Segment to Dominate the Vaccines Market
Based on type, the vaccines market is segmented into subunit & conjugate vaccines, inactivated vaccines, live-attenuated vaccines, toxoid vaccines, and combination vaccines. In 2024, the subunit & conjugate vaccines segment is expected to account for the largest share of the vaccines market. The large market share of this segment can be attributed to the subunit & conjugate vaccines’ long-term immunity, high safety, and stability compared to vaccines with other antigens.
By Valence: In 2024, the Multivalent Vaccines Segment to Dominate the Vaccines Market
Based on valence, the vaccines market is segmented into multivalent vaccines and monovalent vaccines. In 2024, the multivalent vaccines segment is expected to account for the larger share of 64.5% of vaccines market. The large market share of this segment is attributed to the launch of new multivalent vaccines, growing investments by key players in the R&D of multivalent vaccines, and technological advancements in multivalent vaccine production.
Geographical Analysis
In 2024, North America is expected to account for the largest share of 41.2% of the vaccine market, followed by Europe and Asia-Pacific. North America’s significant market share can be attributed to several key factors, including the growing research & development, product launches, and the establishment of new facilities in the region by key players.
However, Asia-Pacific is slated to register the highest growth rate of 3.1% during the forecast period. The growth of this regional market is attributed to the increase in the emergence of infectious diseases, a large population of patients suffering from diseases, rising public awareness for vaccination, and growing support from governments towards immunization.
Vaccines Market: Key Companies
The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted in the last 3–4 years. Some of the key players operating in the vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).
Vaccines Industry Overview: Latest Developments from Key Industry Players
- In May 2024, Sanofi (France) signed an agreement with Novavax, Inc. (U.S.) to develop novel flu-COVID-19 combination vaccines and co-commercialize the COVID-19 vaccine.
- In October 2023, Pfizer Inc. (U.S.) received the U.S. Food and Drug Administration (FDA) approval for PENBRAYA for the prevention of the five most common serogroups causing meningococcal disease in adolescents.
- In June 2021, Sanofi (France) collaborated with Translate Bio (U.S.) to initiate Phase 1 clinical trials to evaluate an mRNA-based investigational vaccine against seasonal influenza.
Vaccines Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
270 |
|
Format |
|
|
Forecast Period |
2024–2031 |
|
Base Year |
2023 |
|
CAGR (Value) |
2.3% |
|
Market Size (Value) |
USD 71.50 billion by 2031 |
|
Segments Covered |
By Indication
By Route of Administration
By Type
By Valence
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, Italy, U.K., Spain, Switzerland, Netherlands, Rest of Europe) Asia–Pacific (India, China, Japan, Australia, South Korea, Rest of Asia–Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East & Africa. |
|
Key Companies |
Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.). |
Key questions answered in the vaccines market report:
The vaccines market encompasses the industry involved in the development, production, and distribution of vaccines used to prevent or treat diseases. This market includes various types of vaccines, such as subunit, conjugate, inactivated, and live-attenuated vaccines, as well as different routes of administration like intramuscular, subcutaneous, and oral.
In 2023, the vaccines market was valued at approximately $59.55 billion.
The market is expected to grow to $71.5 billion by 2031, with an estimated value of $60.98 billion in 2024.
The market size was $59.55 billion in 2023 and is projected to be $60.98 billion in 2024.
Major companies in the vaccines market include:
Sanofi (France)
Merck & Co., Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Pfizer Inc. (U.S.)
Johnson & Johnson (U.S.)
Daiichi Sankyo Co., Ltd. (Japan)
Takeda Pharmaceutical Company Limited (Japan)
CSL Limited (Australia)
The market is experiencing growth driven by technological advancements in vaccine development, a strong product pipeline, and increasing government initiatives towards immunization.
Key drivers include:
- Technological advancements in vaccine administration and development
- Strong product pipeline from major vaccine manufacturers
- Increasing government initiatives and support for immunization
- Rising prevalence of infectious diseases
- Indication: Pneumococcal diseases, influenza, HPV, DTP, meningococcal disease, MMR, rotavirus, polio, hepatitis, COVID-19, and others.
- Type: Subunit & conjugate vaccines, inactivated vaccines, live-attenuated vaccines, toxoid vaccines, and combination vaccines.
The global outlook is positive, with North America holding the largest market share. However, Asia-Pacific is expected to exhibit the highest growth rate due to increasing disease prevalence, rising vaccination awareness, and government support.
The market is projected to grow from $60.98 billion in 2024 to $71.5 billion by 2031, indicating a steady expansion.
The market is projected to grow at a CAGR of 2.3% during the forecast period from 2024 to 2031.
North America is expected to hold the highest market share, accounting for 41.2% of the market in 2024.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Factors Affecting the Market Growth
4.1. Overview
4.2. Drivers
4.2.1. Strong Product Pipeline for Vaccines
4.2.2. Increasing Government Focus on Immunization Programs
4.2.3. Technological Advancements in Vaccine Administration
4.3. Restraints
4.3.1. High Costs Involved in Vaccine Development
4.3.2. Long Timelines of Vaccine Manufacturing
4.4. Opportunities
4.4.1. Rising Prevalence of Diseases
4.4.2. Growing Focus on Therapeutic Vaccines
4.4.3. Growth Prospects in Emerging Markets
4.4.4. Increasing Use of Adjuvants in Vaccines
4.5. Challenges
4.5.1. Product Recalls
4.5.2. Inadequate Access to Vaccines
4.6. Factor Analysis
4.7. Regulatory Analysis
4.8. Pricing Analysis
4.9. Porter’s Five Forces Analysis
5. Vaccines Market Assessment—by Indication
5.1. Overview
5.2. Pneumococcal Diseases
5.3. Influenza
5.4. Human Papillomavirus (HPV)
5.5. Diphtheria, Tetanus, and Pertussis (DTP)
5.6. Meningococcal Disease
5.7. Measles, Mumps, and Rubella (MMR)
5.8. Rotavirus
5.9. Poliomyelitis (Polio)
5.10. Hepatitis
5.11. COVID-19
5.12. Other Indications
6. Vaccines Market Assessment—by Route of Administration
6.1. Overview
6.2. Intramuscular (IM)
6.3. Subcutaneous (SC)
6.4. Oral
6.5. Other Routes of Administration
7. Vaccines Market Assessment—by Type
7.1. Overview
7.2. Subunit & Conjugate Vaccines
7.3. Inactivated Vaccines
7.4. Live-Attenuated Vaccines
7.5. Toxoid Vaccines
7.6. Combination Vaccines
8. Vaccines Market Assessment—by Valence
8.1. Overview
8.2. Multivalent Vaccines
8.3. Monovalent Vaccines
9. Vaccines Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
9.6. Middle East & Africa (MEA)
10. Competition Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis/Market Rankings, by Key Players (2023)
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Sanofi
11.2. Merck & Co., Inc.
11.3. GlaxoSmithKline plc.
11.4. Pfizer, Inc.
11.5. Johnson & Johnson
11.6. Daiichi Sankyo Co., Ltd.
11.7. Takeda Pharmaceutical Company Limited
11.8. CSL Limited
11.9. Emergent BioSolutions Inc.
11.10. AstraZeneca PLC
(Note: SWOT analysis of the top 5 companies will be provided)
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Key Government Regulatory Agencies
Table 2 List of Some of the Promising Vaccines in the Pipeline
Table 3 Average Selling Price (ASP) of Key Vaccines, by Region (USD/Unit)
Table 4 Global Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 5 Global Vaccines Market, by Indication, 2022–2031 (Units)
Table 6 Overview: Pneumococcal Disease
Table 7 Pneumococcal Diseases: Vaccines in the Pipeline
Table 8 Key Companies Offering Pneumococcal Vaccines
Table 9 Global Vaccines Market for Pneumococcal Disease, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Vaccines Market for Pneumococcal Disease, by Country/Region, 2022–2031 (Units)
Table 11 Overview: Influenza
Table 12 Influenza: Vaccines in the Pipeline
Table 13 Key Companies Offering Influenza Vaccines
Table 14 Global Vaccines Market for Influenza, by Country/Region 2022–2031(USD Million)
Table 15 Global Vaccines Market for Influenza, by Country/Region 2022–2031(Units)
Table 16 Overview: HPV
Table 17 HPV Vaccine Prices (As of November 2020)
Table 18 Global Vaccines Market for Human Papillomavirus (HPV), by Country/Region, 2022–2031 (USD Million)
Table 19 Global Vaccines Market for Human Papillomavirus (HPV), by Country/Region, 2022–2031 (Units)
Table 20 Overview: Diphtheria, Tetanus, and Pertussis (DTP)
Table 21 Key Companies Offering DTP Vaccines
Table 22 Global Vaccines Market for Diphtheria, Tetanus, and Pertussis (DTP), by Country/Region, 2022–2031 (USD Million)
Table 23 Global Vaccines Market for Diphtheria, Tetanus, and Pertussis (DTP), by Country/Region, 2022–2031 (Units)
Table 24 Overview: Meningococcal Disease
Table 25 Marketed Meningococcal Vaccine Combinations
Table 26 Key Companies Offering Meningococcal Vaccines
Table 27 Global Vaccines Market for Meningococcal Disease, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Vaccines Market for Meningococcal Disease, by Country/Region, 2022–2031 (Units)
Table 29 Overview: Measles, Mumps, and Rubella
Table 30 Key Companies Offering MMR Vaccines
Table 31 Global Vaccines Market for Measles, Mumps, and Rubella (MMR), by Country/Region, 2022–2031 (USD Million)
Table 32 Global Vaccines Market for Measles, Mumps, and Rubella (MMR), by Country/Region, 2022–2031 (Units)
Table 33 Overview: Rotavirus Disease
Table 34 Key Companies Offering Rotavirus Vaccines
Table 35 Global Vaccines Market for Rotavirus, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Vaccines Market for Rotavirus, by Country/Region, 2022–2031 (Units)
Table 37 Overview: Poliomyelitis (Polio)
Table 38 Polio Cases and Endemic Countries
Table 39 Key Companies Offering Polio Vaccines
Table 40 Global Vaccines Market for Polio, by Country/Region, 2022–2031 (USD Million)
Table 41 Global Vaccines Market for Polio, by Country/Region, 2022–2031 (Units)
Table 42 Overview: Hepatitis A
Table 43 Overview: Hepatitis B
Table 44 Key Companies Offering Hepatitis Vaccines
Table 45 Global Vaccines Market for Hepatitis, by Country/Region, 2022–2031 (USD Million)
Table 46 Global Vaccines Market for Hepatitis, by Country/Region, 2022–2031 (Units)
Table 47 Global Vaccines Market for COVID-19, by Country/Region, 2022–2031 (USD Million)
Table 48 Global Vaccines Market for COVID-19, by Country/Region, 2022–2031 (Units)
Table 49 Global Vaccines Market for Other Indications, by Country/Region, 2022–2031 (USD Million)
Table 50 Global Vaccines Market for Other Indications, by Country/Region, 2022–2031 (Units)
Table 51 Global Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 52 Intramuscular Sites of Vaccine Administration, by Age Group
Table 53 Vaccines for Intramuscular Administration
Table 54 Key Companies Offering Intramuscular Vaccines
Table 55 Global Intramuscular Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 56 Administration Sites for Subcutaneous Vaccines, by Age Group
Table 57 Vaccines for Subcutaneous Administration
Table 58 Key Companies Offering Subcutaneous Vaccines
Table 59 Global Subcutaneous Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 60 Key Companies Offering Oral Vaccines
Table 61 Global Oral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 62 Global Vaccines Market for Other Routes of Administration, by Country/Region, 2022–2031 (USD Million)
Table 63 Types of Vaccines, by Antigen
Table 64 Global Vaccines Market, by Type, 2022–2031 (USD Million)
Table 65 Companies Offering Subunit and Conjugate Vaccines
Table 66 Global Subunit & Conjugate Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 67 Approved Inactivated Coronavirus Vaccines (As of 23/07/2021)
Table 68 Global Inactivated Coronavirus Vaccines in Development (As of 23/07/2021)
Table 69 Companies Offering Inactivated Vaccines
Table 70 Global Inactivated Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 71 Live-Attenuated COVID-19 Candidate Vaccines
Table 72 Companies Offering Live-Attenuated Vaccines
Table 73 Global Live-Attenuated Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 74 Global Toxoid Vaccines Used in the Vaccination Schedule
Table 75 Companies Offering Toxoid Vaccines
Table 76 Global Toxoid Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 77 Companies Offering Combination Vaccines
Table 78 Global Combination Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 79 Global Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 80 Multivalent Vaccines for Children (Available)
Table 81 Companies Offering Multivalent Vaccines
Table 82 Global Multivalent Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 83 Malaria, Ebola, Dengue, and Coronavirus Vaccines in the Pipeline
Table 84 Companies Offering Monovalent Vaccines
Table 85 Global Monovalent Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 86 Global Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 87 North America: Vaccines Market, by Country, 2022–2031 (USD Million)
Table 88 North America: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 89 North America: Vaccines Market, by Indication, 2022–2031 (Units)
Table 90 North America: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 91 North America: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 92 North America: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 93 Influenza Burden in the U.S., 2010–2020
Table 94 Some of the Coronavirus Vaccines in Development in the U.S. (As of 24/06/2021)
Table 95 U.S.: Macro Indicators
Table 96 U.S.: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 97 U.S.: Vaccines Market, by Indication, 2022–2031 (Units)
Table 98 U.S.: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 99 U.S.: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 100 U.S.: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 101 Canada: Macro Indicators
Table 102 Canada: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 103 Canada: Vaccines Market, by Indication, 2022–2031 (Units)
Table 104 Canada: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 105 Canada: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 106 Canada: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 107 Europe: Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 108 Europe: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 109 Europe: Vaccines Market, by Indication, 2022–2031 (Units)
Table 110 Europe: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 111 Europe: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 112 Europe: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 113 Germany: Macro Indicators
Table 114 Germany: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 115 Germany: Vaccines Market, by Indication, 2022–2031 (Units)
Table 116 Germany: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 117 Germany: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 118 Germany: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 119 U.K.: Macro Indicators
Table 120 U.K.: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 121 U.K.: Vaccines Market, by Indication, 2022–2031 (Units)
Table 122 U.K.: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 123 U.K.: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 124 U.K.: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 125 France: Macro Indicators
Table 126 France: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 127 France: Vaccines Market, by Indication, 2022–2031 (Units)
Table 128 France: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 129 France: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 130 France: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 131 Italy: Macro Indicators
Table 132 Italy: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 133 Italy: Vaccines Market, by Indication, 2022–2031 (Units)
Table 134 Italy: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 135 Italy: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 136 Italy: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 137 Spain: Macro Indicators
Table 138 Spain: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 139 Spain: Vaccines Market, by Indication, 2022–2031 (Units)
Table 140 Spain: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 141 Spain: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 142 Spain: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 143 Switzerland: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 144 Switzerland: Vaccines Market, by Indication, 2022–2031 (Units)
Table 145 Switzerland: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 146 Switzerland: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 147 Switzerland: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 148 Netherlands: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 149 Netherlands: Vaccines Market, by Indication, 2022–2031 (Units)
Table 150 Netherlands: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 151 Netherlands: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 152 Netherlands: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 153 Rest of Europe: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 154 Rest of Europe: Vaccines Market, by Indication, 2022–2031 (Units)
Table 155 Rest of Europe: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 156 Rest of Europe: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 157 Rest of Europe: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 158 Asia-Pacific: Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 159 Asia-Pacific: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 160 Asia-Pacific: Vaccines Market, by Indication, 2022–2031 (Units)
Table 161 Asia-Pacific: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 162 Asia-Pacific: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 163 Asia-Pacific: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 164 Japan: Macro Indicators
Table 165 Japan: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 166 Japan: Vaccines Market, by Indication, 2022–2031 (Units)
Table 167 Japan: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 168 Japan: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 169 Japan: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 170 Coronavirus Vaccines Approved/In Development in China (As of 03/01/2021)
Table 171 China: Macro Indicators
Table 172 China: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 173 China: Vaccines Market, by Indication, 2022–2031 (Units)
Table 174 China: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 175 China: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 176 China: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 177 Vaccine Prices in India
Table 178 India: Macro Indicators
Table 179 India: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 180 India: Vaccines Market, by Indication, 2022–2031 (Units)
Table 181 India: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 182 India: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 183 India: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 184 Australia: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 185 Australia: Vaccines Market, by Indication, 2022–2031 (Units)
Table 186 Australia: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 187 Australia: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 188 Australia: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 189 South Korea: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 190 South Korea: Vaccines Market, by Indication, 2022–2031 (Units)
Table 191 South Korea: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 192 South Korea: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 193 South Korea: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 194 Rest of Asia-Pacific: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 195 Rest of Asia-Pacific: Vaccines Market, by Indication, 2022–2031 (Units)
Table 196 Rest of Asia-Pacific: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 197 Rest of Asia-Pacific: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 198 Rest of Asia-Pacific: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 199 Latin America: Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 200 Latin America: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 201 Latin America: Vaccines Market, by Indication, 2022–2031 (Units)
Table 202 Latin America: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 203 Latin America: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 204 Latin America: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 205 Brazil: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 206 Brazil: Vaccines Market, by Indication, 2022–2031 (Units)
Table 207 Brazil: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 208 Brazil: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 209 Brazil: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 210 Mexico: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 211 Mexico: Vaccines Market, by Indication, 2022–2031 (Units)
Table 212 Mexico: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 213 Mexico: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 214 Mexico: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 215 Rest of Latin America: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 216 Rest of Latin America: Vaccines Market, by Indication, 2022–2031 (Units)
Table 217 Rest of Latin America: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 218 Rest of Latin America: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 219 Rest of Latin America: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 220 Middle East & Africa: Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 221 Middle East & Africa: Vaccines Market, by Indication, 2022–2031 (Units)
Table 222 Middle East & Africa: Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 223 Middle East & Africa: Vaccines Market, by Type, 2022–2031 (USD Million)
Table 224 Middle East & Africa: Vaccines Market, by Valence, 2022–2031 (USD Million)
Table 225 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Vaccines Market, by Indication, 2024 Vs. 2031 (USD Million)
Figure 8 COVID-19 Vaccines Market 2021 Vs. 2028 (USD Million)
Figure 9 Global Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
Figure 10 Global Vaccines Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 11 Global Vaccines Market, by Valence, 2024 Vs. 2031 (USD Million)
Figure 12 Vaccines Market Overview, by Region
Figure 13 Number of Health Products in the Pipeline: July 2021
Figure 14 Vaccine Projects in the Pipeline: 2020
Figure 15 Therapeutic Vaccines Being Developed for Cancer: 2018 and 2022
Figure 16 New Cancer Cases in Asia, Latin America, and the Caribbean: 2020–2040
Figure 17 Global Vaccines Market, by Indication, 2024 Vs.2031 (USD Million)
Figure 18 Influenza Vaccines Distribution: 2016–2021
Figure 19 Forecasted Global Demand for DTwP Vaccines: 2018–2032
Figure 20 MMR Vaccines Supply: 2016–2019
Figure 21 Global Vaccination Coverage Against Rotavirus: 2010–2022
Figure 22 U.S. Funding for Polio: 2015–2020
Figure 23 Routes of Vaccine Administration
Figure 24 Global Vaccines Market, by Indication, 2024 Vs. 2031 (USD Million)
Figure 25 Global Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
Figure 26 Global Vaccines Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 27 Global Vaccines Market, by Valence, 2024 Vs. 2031 (USD Million)
Figure 28 Coronavirus Vaccines in Development, by Phase
Figure 29 COVID-19 Vaccination Among Populations (Latest Available Data)
Figure 30 Global Vaccines Market, by Region, 2024Vs. 2031 (USD Million)
Figure 31 Geographic Snapshot: North America Vaccines Market
Figure 32 U.S. Funding for Global Polio: 2013–2020
Figure 33 Geographic Snapshot: Europe Vaccines Market
Figure 34 Increase in Immunization After Mandatory Vaccination
Figure 35 Increase in the Number of Registered Influenza Cases (2015–2022)
Figure 36 Spain: Increase in the Number of Biotechnology Companies (2010–2022)
Figure 37 Geographic Snapshot: Asia-Pacific Vaccines Market
Figure 38 India: Increase in Health Expenditure (2010–2022)
Figure 39 Cancer Incidence in the Middle East & Africa: 2020 and 2030
Figure 40 Geographic Snapshot: Latin America Vaccines Market
Figure 41 Key Growth Strategies Adopted by Leading Players, 2018–2021
Figure 42 Vaccines Market: Competitive Benchmarking, by Geography
Figure 43 Global Vaccines Market Share Analysis, by Key Player, 2023 (%)
Figure 44 Sanofi: Financial Overview (2023)
Figure 45 Merck & Co., Inc.: Financial Overview (2023)
Figure 46 GlaxoSmithKline plc (GSK): Financial Overview (2020)
Figure 47 Pfizer, Inc.: Financial Overview (2023)
Figure 48 Johnson & Johnson (J&J): Financial Overview (2023)
Figure 49 Daichi Sankyo Co., Ltd.: Financial Overview (2023)
Figure 50 Takeda Pharmaceutical: Financial Overview (2023)
Figure 51 CSL Limited: Financial Overview (2023)
Figure 52 Emergent BioSolutions Inc.: Financial Overview (2023)
Figure 53 AstraZeneca PLC: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Viral Vaccines Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Nov-2024
Veterinary Vaccines Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Anesthesia Machines Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jun-2024
Vaccine Storage Equipment Market - Global Opportunity Analysis and Industry Forecast (2020-2027)
Published Date: Jan-2021
